Karolinska Development announces Chairman Bo Jesper Hansen and CEO Jim Van heusden's decision to Step Down, and the promotion of Viktor Drvota to CEO
STOCKHOLM - APRIL 20, 2017.
Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that Bo Jesper Hansen, MD, PhD, Chairman of the Company's Board, has informed Karolinska Development's Nomination Committee that he will not stand for re-election at the 2017 Annual General Meeting. The Nomination Committee's proposals will be announced in a separate press release in connection with the notice of the 2017 Annual General Meeting which is due to take place on 24 May 2017.
Bo Jesper Hansen was appointed as Chairman in 2013. Under his chairmanship, he initiated the successful transformation of Karolinska Development from a wide-ranging collection of early stage science-driven projects into a highly focused investment company with a portfolio of business-driven companies capable of delivering significant shareholder value.
"Bo Jesper Hansen's broad industry and leadership experience has been crucial in guiding Karolinska Development through the most significant changes in the Company's history. We would like to thank him for his considerable efforts that have created a strong platform for Karolinska Development's future success." said Niclas Adler, chairman of the Nomination Committee of Karolinska Development.
Karolinska Development also announces that its CEO, Jim Van heusden, PhD, has tendered his resignation and will formally leave the Company at the end of October 2017.
"Jim Van heusden has done a remarkable job as the CEO of Karolinska Development. Under his leadership, he successfully executed a major strategic turn-around that has positioned the Company to become a leading Nordic life science investment company. Karolinska Development is now in an excellent shape, with its portfolio companies poised to deliver significant value generating milestones in the coming 12 - 18 months. With the strategic turn-around now complete we understand Jim's desire to look for new opportunities and wish him every success for the future," said Bo Jesper Hansen, Chairman of the Board of Karolinska Development.
"I would like to thank Bo Jesper Hansen and the Board for their unwavering support during the major strategic turn-around that we have implemented in the last two years. With these changes now finished I believe it is the appropriate time for me to look for a new challenge. I am very proud of what we have achieved together and am convinced Karolinska Development is now in a much stronger position to deliver value for all its stakeholders from its portfolio of exciting therapeutic and med-tech companies." says Jim Van heusden, CEO of Karolinska Development.
The Board of Directors is pleased to announce the promotion of Viktor Drvota MD PhD as the Company's Chief Executive Officer, effective June 1 2017. Dr Drvota is currently Karolinska Development's Deputy Chief Executive Officer and Chief Investment Officer.
Bo Jesper Hansen, Chairman of the Board of Karolinska Development says: "I am extremely pleased to announce Viktor's promotion to the role of CEO. Since joining the Company in early 2016, Viktor has made an important contribution to the strategic turnaround that we have implemented. With his significant life sciences investment experience, centered on the Nordic region, and his impressive track record, Viktor is the ideal person to lead Karolinska Development through the next phase of its development."
Dr Drvota joined Karolinska Development as Chief Investment Officer in February 2016 and was promoted Deputy Chief Executive Officer in March 2017. Dr Drvota brings more than 15 years of life science investment experience. Prior to joining Karolinska Development he worked at SEB Venture Capital, where he was Head of Life Science from 2002 and a senior investment manager. Before joining SEB, Viktor was a practicing cardiologist at Huddinge University Hospital in Stockholm. He has been an Associate Professor in Cardiology at Karolinska Institutet, Stockholm, since 2002.
Dr Drvota says: "I am thrilled to take on the role of CEO in addition to my current position as Chief Investment Officer. With the Company's strategic turnaround now complete, Karolinska Development is in excellent shape to deliver significant shareholder value as its portfolio companies deliver a number of important clinical and commercial milestones over the next 12 to 18 months."
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: email@example.com
Viktor Drvota, Chief Investment Officer and Deputy CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.comThis information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Jim Van heusden, at 08:00 am CEST on 20 April 2017.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Canada's CoinField cryptocurrency exchange going international with commission-free trading app moonGO through a new partnership23.7.2018 11:30 | Pressmeddelande
moonGO(TM) app is the fastest and most reliable way to buy/sell and store cryptocurrencies. The app allows users to convert cryptos directly to EUR/USD to be loaded into their moonGo(TM) card and be used anywhere worldwide whether they're shopping online or spending it at a physical retailer who accepts credit cards. VANCOUVER, British Columbia, July 23, 2018 (GLOBE NEWSWIRE) -- CoinField, the most advanced cryptocurrency exchange in Canada is now extending its services worldwide thanks to a new partnership with Malta's Manticore Ventures to create moonGO(TM), a powerful app designed for traders who thrive on agility, flexibility and security. With moonGO(TM), users can set up their trading accounts in about 60 seconds, withdraw fiat currency as Euro or US dollars in the form of moonGO(TM) cards, and use the moonGO(TM) cards to make purchases online or at any retailer that accepts credit cards. The moonGO(TM) app will take CoinField's sterling reputation outside of Canada and make its
UK drafts new M. genitalium guidelines: Resistance Guided Therapy to tackle antibiotic resistance23.7.2018 09:00 | Pressmeddelande
BASHH aiming to raise awareness of Mgen and curb rising antibiotic resistance LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- The British Association of Sexual Health and HIV (BASHH) draft guidelines for the sexually transmitted infection Mycoplasma genitalium (Mgen) were posted for consultation on July 8th, 20181[link]. The guideline recommends Resistance Guided Therapy as best practice when treating an Mgen infection, with a strong recommendation for diagnostic tests to direct appropriate antibiotic treatment. Mgen is highly resistant to antibiotics, up to 50% of infections are already resistant to the first-line treatment, azithromycin.2,3 This rate may rise if infections are treated without knowledge of resistance status. The success of Resistance Guided Therapy as treatment for Mgen was published in Clinical Infectious Diseases, June 20182 [link].Cure rates increased from under 68% to over 92% by switching the first-line drug and using the SpeeDx Resistance Plus® MG* test to triage pati
LeoVegas AB: Inbjudan till presentation av LeoVegas delårsrapport för andra kvartalet 201823.7.2018 08:00 | Pressmeddelande
LeoVegas delårsrapport för det andra kvartalet för 2018 kommer att publiceras klockan 08:00 den 1:a augusti 2018. En webbsänd telefonkonferens kommer att hållas klockan 09:00 samma dag där Gustaf Hagman, VD och medgrundare samt Viktor Fritzén, CFO, presenterar resultatet. Det kommer att finnas möjlighet att ställa frågor via webbsändningen där även presentationsmaterialet går att följa. Webbsändningen nås på adressen: https://edge.media-server.com/m6/p/zupwii5n För att delta i telefonkonferensen via telefon, vänligen ring in på något av följande nummer: SE: +46 (0) 8 5664 2753 UK: +44 (0) 330 336 9128 US: +1 646 828 8144 Bekräftelse kod: 5362090 Webbsändningen, som även kan ses i efterhand, och presentationsmaterialet kommer att finnas tillgängligt på LeoVegas webbplats www.leovegasgroup.com under Investor Relations. För ytterligare information, vänligen kontakta: Gustaf Hagman, Group CEO och medgrundare: +46 (0) 8 410 367 66, email@example.com Philip Doftvik, Head of Investor
LeoVegas AB: Invitation to presentation of LeoVegas second quarter 201823.7.2018 08:00 | Pressmeddelande
LeoVegas interim report for the second quarter for 2018 will be published at 08:00 CET on August 1, 2018. A webcast telephone conference will be held at 09:00 CET the same day, where Gustaf Hagman, CEO and Co-founder, and Viktor Fritzén, CFO, will present the results. A possibility will be given to ask questions via the webcast and follow the presentation live. The webcast will be accessible at: https://edge.media-server.com/m6/p/zupwii5n To participate in the conference call by phone, please call one of the following numbers: SE: +46 (0) 8 5664 2753 UK: +44 (0) 330 336 9128 US: +1 646 828 8144 Confirmation code: 5362090 The webcast, which afterwards also will be available on demand, and presentation material will be published on LeoVegas website, www.leovegasgroup.com under Investor Relations. For further information, please contact: Gustaf Hagman, Group CEO: +46 (0) 8 410 367 66, firstname.lastname@example.org Philip Doftvik, Head of Investor Relations and corporate finance: +46 73 512 0
Gratomic Announces Non-Brokered Private Placement21.7.2018 19:41 | Pressmeddelande
TORONTO, July 21, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A143MR) is pleased to announce the offering of a non-brokered private placement of up to 20,000,000 working capital units (the "WC Unit") for up to $2,000,000 (the "Offering"). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant ("WC Warrant"). Each WC Warrant entitles the holder to purchase one (1) common share (a "WC Warrant Share") at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the "Final Trading Day") is at least four (4) months from the Closing Date, the date which is thirty (30) days from the Final Trading Day. Eligible Finders may receive 5% of the value of
eGain Enables Conversational Customer Service Through Apple Business Chat20.7.2018 12:30 | Pressmeddelande
SUNNYVALE, Calif. and NEWBURY, United Kingdom, July 20, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud-based customer engagement solutions, today announced its integration with Apple Business Chat. According to Gartner, requests for customer support through consumer mobile messaging apps will exceed requests for customer support through traditional social media by 2019*. Moreover, 56% of consumers surveyed in a Nielsen study would rather message a business than call customer service, and 67% expect to message businesses even more over the next two years. Key capabilities Among key capabilities of the integrated solution are: Enabling hundreds of millions of consumers on iPhone and iPad to interact with businesses through the Messages app Leverage eGain AI to infer customer intent, power bot conversations through messaging, route escalations to contact center agents, and guide agents through messaging conversations Provide immersive customer experiences with
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum